View in EDS PDF Full Text

Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021.

Saved in:
Bibliographic Details
Title: Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021.
Alternate Title: Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention.
Authors: Brotons, Carlos1 cbrotons@eapsardenya.cat, Camafort, Miguel2, Mar Castellanos, María del3, Clarà, Albert4, Cortés, Olga5, Diaz Rodríguez, Ángel6, Elosua, Roberto7, Gorostidi, Manuel8, Hernández, Antonio M.9, Herranz, María10, Justo, Soledad11, Lahoz, Carlos2, Niño, Pilar12, Pallarés-Carratalá, Vicente6, Pedro-Botet, Juan13, Pérez Pérez, Antonio9, Ángel Royo-Bordonada, Miguel14, Santamaría, Rafael8, Tresserras, Ricard15, Zamora, Alberto13
Source: Nefrologia. May/Jun2023, Vol. 43 Issue 3, p360-369. 10p.
Subjects: CARDIOVASCULAR diseases risk factors, CHRONIC kidney failure, GLYCEMIC control, CARDIOVASCULAR diseases, GLOMERULAR filtration rate
Abstract (English): We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease prevention in clinical practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular diseases risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (step 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular diseases risk, lifetime cardiovascular diseases risk and treatment benefit, comorbidities and patient preferences. The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal cardiovascular diseases events (myocardial infarction, stroke and vascular mortality) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according different age groups (< 50, 50-69, ≥ 70 years). Different flow charts of cardiovascular diseases risk and risk factor treatment in apparently healthy persons, in diabetic patients, and in patients with established atherosclerotic cardiovascular diseases are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Presentamos la adaptación española de las Guías Europeas de Prevención Cardiovascular 2021. En esta actualización, además del abordaje individual, se pone mucho más énfasis en las políticas sanitarias como estrategia de prevención poblacional. Se recomienda el cálculo del riesgo vascular de manera sistemática a todas las personas adultas con algún factor de riesgo vascular. Los objetivos terapéuticos para el colesterol LDL, la presión arterial y la glucemia no han cambiado respecto a las anteriores guías, pero se recomienda alcanzar estos objetivos de forma escalonada (etapas 1 y 2). Se recomienda llegar siempre hasta la etapa 2, y la intensificación del tratamiento dependerá del riesgo a los 10 años y de por vida, del beneficio del tratamiento, de las comorbilidades, de la fragilidad y de las preferencias de los pacientes. Las guías presentan por primera vez un nuevo modelo para calcular el riesgo SCORE2 y SCORE2-OP de morbimortalidad vascular en los próximos 10 años (infarto de miocardio, ictus y mortalidad vascular) en hombres y mujeres entre 40 y 89 años. Otra de las novedades sustanciales es el establecimiento de diferentes umbrales de riesgo dependiendo de la edad (< 50, 50-69, ≥ 70 años). Se presentan diferentes algoritmos de cálculo del riesgo vascular y tratamiento de los factores de riesgo vascular para personas aparentemente sanas, pacientes con diabetes y pacientes con enfermedad vascular aterosclerótica. Los pacientes con enfermedad renal crónica se considerarán de riesgo alto o muy alto según la tasa del filtrado glomerular y el cociente albúmina/creatinina. Se incluyen innovaciones en las recomendaciones sobre los estilos de vida, adaptadas a las recomendaciones del Ministerio de Sanidad, así como aspectos novedosos relacionados con el control de los lípidos, la presión arterial, la diabetes y la insuficiencia renal crónica. [ABSTRACT FROM AUTHOR]
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 163675154
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comentario del CEIPV a las nuevas Gu&#237;as Europeas de Prevenci&#243;n Cardiovascular 2021.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Brotons%2C+Carlos%22&quot;&gt;Brotons, Carlos&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;i&gt; cbrotons@eapsardenya.cat&lt;/i&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Camafort%2C+Miguel%22&quot;&gt;Camafort, Miguel&lt;/searchLink&gt;&lt;relatesTo&gt;2&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mar+Castellanos%2C+Mar&#237;a+del%22&quot;&gt;Mar Castellanos, Mar&#237;a del&lt;/searchLink&gt;&lt;relatesTo&gt;3&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Clar&#224;%2C+Albert%22&quot;&gt;Clar&#224;, Albert&lt;/searchLink&gt;&lt;relatesTo&gt;4&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cort&#233;s%2C+Olga%22&quot;&gt;Cort&#233;s, Olga&lt;/searchLink&gt;&lt;relatesTo&gt;5&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Diaz+Rodr&#237;guez%2C+&#193;ngel%22&quot;&gt;Diaz Rodr&#237;guez, &#193;ngel&lt;/searchLink&gt;&lt;relatesTo&gt;6&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Elosua%2C+Roberto%22&quot;&gt;Elosua, Roberto&lt;/searchLink&gt;&lt;relatesTo&gt;7&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gorostidi%2C+Manuel%22&quot;&gt;Gorostidi, Manuel&lt;/searchLink&gt;&lt;relatesTo&gt;8&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hern&#225;ndez%2C+Antonio+M%2E%22&quot;&gt;Hern&#225;ndez, Antonio M.&lt;/searchLink&gt;&lt;relatesTo&gt;9&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Herranz%2C+Mar&#237;a%22&quot;&gt;Herranz, Mar&#237;a&lt;/searchLink&gt;&lt;relatesTo&gt;10&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Justo%2C+Soledad%22&quot;&gt;Justo, Soledad&lt;/searchLink&gt;&lt;relatesTo&gt;11&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lahoz%2C+Carlos%22&quot;&gt;Lahoz, Carlos&lt;/searchLink&gt;&lt;relatesTo&gt;2&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ni&#241;o%2C+Pilar%22&quot;&gt;Ni&#241;o, Pilar&lt;/searchLink&gt;&lt;relatesTo&gt;12&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pallar&#233;s-Carratal&#225;%2C+Vicente%22&quot;&gt;Pallar&#233;s-Carratal&#225;, Vicente&lt;/searchLink&gt;&lt;relatesTo&gt;6&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pedro-Botet%2C+Juan%22&quot;&gt;Pedro-Botet, Juan&lt;/searchLink&gt;&lt;relatesTo&gt;13&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22P&#233;rez+P&#233;rez%2C+Antonio%22&quot;&gt;P&#233;rez P&#233;rez, Antonio&lt;/searchLink&gt;&lt;relatesTo&gt;9&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22&#193;ngel+Royo-Bordonada%2C+Miguel%22&quot;&gt;&#193;ngel Royo-Bordonada, Miguel&lt;/searchLink&gt;&lt;relatesTo&gt;14&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Santamar&#237;a%2C+Rafael%22&quot;&gt;Santamar&#237;a, Rafael&lt;/searchLink&gt;&lt;relatesTo&gt;8&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tresserras%2C+Ricard%22&quot;&gt;Tresserras, Ricard&lt;/searchLink&gt;&lt;relatesTo&gt;15&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Zamora%2C+Alberto%22&quot;&gt;Zamora, Alberto&lt;/searchLink&gt;&lt;relatesTo&gt;13&lt;/relatesTo&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Nefrologia%22&quot;&gt;Nefrologia&lt;/searchLink&gt;. May/Jun2023, Vol. 43 Issue 3, p360-369. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CARDIOVASCULAR+diseases+risk+factors%22&quot;&gt;CARDIOVASCULAR diseases risk factors&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CHRONIC+kidney+failure%22&quot;&gt;CHRONIC kidney failure&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22GLYCEMIC+control%22&quot;&gt;GLYCEMIC control&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CARDIOVASCULAR+diseases%22&quot;&gt;CARDIOVASCULAR diseases&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22GLOMERULAR+filtration+rate%22&quot;&gt;GLOMERULAR filtration rate&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease prevention in clinical practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular diseases risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (step 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular diseases risk, lifetime cardiovascular diseases risk and treatment benefit, comorbidities and patient preferences. The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual&#39;s 10-year risk of fatal and non-fatal cardiovascular diseases events (myocardial infarction, stroke and vascular mortality) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according different age groups (&lt; 50, 50-69, ≥ 70 years). Different flow charts of cardiovascular diseases risk and risk factor treatment in apparently healthy persons, in diabetic patients, and in patients with established atherosclerotic cardiovascular diseases are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Presentamos la adaptaci&#243;n espa&#241;ola de las Gu&#237;as Europeas de Prevenci&#243;n Cardiovascular 2021. En esta actualizaci&#243;n, adem&#225;s del abordaje individual, se pone mucho m&#225;s &#233;nfasis en las pol&#237;ticas sanitarias como estrategia de prevenci&#243;n poblacional. Se recomienda el c&#225;lculo del riesgo vascular de manera sistem&#225;tica a todas las personas adultas con alg&#250;n factor de riesgo vascular. Los objetivos terap&#233;uticos para el colesterol LDL, la presi&#243;n arterial y la glucemia no han cambiado respecto a las anteriores gu&#237;as, pero se recomienda alcanzar estos objetivos de forma escalonada (etapas 1 y 2). Se recomienda llegar siempre hasta la etapa 2, y la intensificaci&#243;n del tratamiento depender&#225; del riesgo a los 10 a&#241;os y de por vida, del beneficio del tratamiento, de las comorbilidades, de la fragilidad y de las preferencias de los pacientes. Las gu&#237;as presentan por primera vez un nuevo modelo para calcular el riesgo SCORE2 y SCORE2-OP de morbimortalidad vascular en los pr&#243;ximos 10 a&#241;os (infarto de miocardio, ictus y mortalidad vascular) en hombres y mujeres entre 40 y 89 a&#241;os. Otra de las novedades sustanciales es el establecimiento de diferentes umbrales de riesgo dependiendo de la edad (&lt; 50, 50-69, ≥ 70 a&#241;os). Se presentan diferentes algoritmos de c&#225;lculo del riesgo vascular y tratamiento de los factores de riesgo vascular para personas aparentemente sanas, pacientes con diabetes y pacientes con enfermedad vascular ateroscler&#243;tica. Los pacientes con enfermedad renal cr&#243;nica se considerar&#225;n de riesgo alto o muy alto seg&#250;n la tasa del filtrado glomerular y el cociente alb&#250;mina/creatinina. Se incluyen innovaciones en las recomendaciones sobre los estilos de vida, adaptadas a las recomendaciones del Ministerio de Sanidad, as&#237; como aspectos novedosos relacionados con el control de los l&#237;pidos, la presi&#243;n arterial, la diabetes y la insuficiencia renal cr&#243;nica. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=163675154
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.nefro.2022.05.003
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 360
    Subjects:
      – SubjectFull: CARDIOVASCULAR diseases risk factors
        Type: general
      – SubjectFull: CHRONIC kidney failure
        Type: general
      – SubjectFull: GLYCEMIC control
        Type: general
      – SubjectFull: CARDIOVASCULAR diseases
        Type: general
      – SubjectFull: GLOMERULAR filtration rate
        Type: general
    Titles:
      – TitleFull: Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brotons, Carlos
      – PersonEntity:
          Name:
            NameFull: Camafort, Miguel
      – PersonEntity:
          Name:
            NameFull: Mar Castellanos, María del
      – PersonEntity:
          Name:
            NameFull: Clarà, Albert
      – PersonEntity:
          Name:
            NameFull: Cortés, Olga
      – PersonEntity:
          Name:
            NameFull: Diaz Rodríguez, Ángel
      – PersonEntity:
          Name:
            NameFull: Elosua, Roberto
      – PersonEntity:
          Name:
            NameFull: Gorostidi, Manuel
      – PersonEntity:
          Name:
            NameFull: Hernández, Antonio M.
      – PersonEntity:
          Name:
            NameFull: Herranz, María
      – PersonEntity:
          Name:
            NameFull: Justo, Soledad
      – PersonEntity:
          Name:
            NameFull: Lahoz, Carlos
      – PersonEntity:
          Name:
            NameFull: Niño, Pilar
      – PersonEntity:
          Name:
            NameFull: Pallarés-Carratalá, Vicente
      – PersonEntity:
          Name:
            NameFull: Pedro-Botet, Juan
      – PersonEntity:
          Name:
            NameFull: Pérez Pérez, Antonio
      – PersonEntity:
          Name:
            NameFull: Ángel Royo-Bordonada, Miguel
      – PersonEntity:
          Name:
            NameFull: Santamaría, Rafael
      – PersonEntity:
          Name:
            NameFull: Tresserras, Ricard
      – PersonEntity:
          Name:
            NameFull: Zamora, Alberto
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May/Jun2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 02116995
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Nefrologia
              Type: main
ResultId 1